Oncolytics Expands Pelareorep Patent Portfolio, Targeting Protection Into the Late 2040s

Key Points

• Oncolytics has secured a new patent in several countries covering pelareorep’s use as a cancer immunotherapy, with a corresponding U.S. patent expected soon.
• Existing patents protect the company’s manufacturing processes through 2044.
• Three patent application families remain pending, including applications covering treatment uses and combination therapies.
• The company plans to seek faster U.S. review for one application this quarter.
• A modified, “next-generation” version of pelareorep could add another layer of patent protection, but its potential benefits still require further study.

Oncolytics Biotech (NASDAQ: ONCY) is expanding its patent portfolio to protect how pelareorep is manufactured, how it is used to treat cancer and a possible next-generation version of the therapy.

The company aims to extend protection for specific treatment uses and future innovations into the late 2040s. Some patents have already been issued, while other parts of that strategy depend on pending applications and future filings.

New Treatment-Use Patent Adds to Manufacturing Protection

A new method-of-use patent covering pelareorep as a cancer immunotherapy has been issued in several countries. Oncolytics expects the corresponding U.S. patent to be issued in the near term.

A method-of-use patent protects specified ways of using a treatment. It adds a different layer of protection from the company’s existing manufacturing patents, which run through 2044.

Oncolytics expects its new treatment-use patents, once issued, to protect their covered applications into the late 2040s. The actual scope and duration will depend on the claims granted, filing dates and patent rules in each country.

Company Plans Faster Review for One Pending Application

Oncolytics has three patent application families pending. These include applications addressing pelareorep’s use with immunotherapies and targeted cancer treatments.

This quarter, the company plans to seek U.S. Track One prioritized examination for one application covering pelareorep’s ability to induce immune responses.

The program aims to reach a final decision within approximately 12 months after prioritized status is granted. It can shorten the review process, but it does not guarantee that a patent will be approved.

Next-Generation Pelareorep Could Provide Additional Protection

Oncolytics is also working with an academic partner on a modified version of pelareorep.

The company expects that work to support a new composition-of-matter patent, which would cover the modified therapy itself rather than only its manufacturing process or treatment uses. Such protection could last up to 20 years from the applicable filing date.

The modified version is being developed with the hope of improving efficacy. That potential improvement has not yet been established and will require further studies.

Pelareorep Remains an Investigational Cancer Therapy

Pelareorep is delivered intravenously and is designed to work in two ways: by selectively replicating in tumor cells and by activating immune responses against cancer.

The company says it has been administered to more than 1,200 patients. Clinical studies have explored its potential to enhance checkpoint inhibitors and other cancer treatments across multiple solid tumor types.

This announcement concerns intellectual property. It does not report new clinical results or a regulatory approval.

Investor Takeaway: More Layers of Protection, With Important Steps Still Ahead

For ONCY investors, the update outlines a strategy to build longer-lasting protection around pelareorep and its potential future versions. That could support the company’s long-term development and partnering efforts.

However, protection into the late 2040s is not fully secured across the entire portfolio. Key steps include issuance of the expected U.S. patent, decisions on pending applications and progress on the modified therapy. Patent protection also does not establish clinical success or guarantee commercial value.